tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

TAK Stock Latest News

Takeda reports Q1 core EPS 151 yen vs. 176 yen last year
The FlyTakeda reports Q1 core EPS 151 yen vs. 176 yen last year
10h ago
TAK
Takeda backs FY25 core EPS view 485 yen
PremiumThe Fly
Takeda backs FY25 core EPS view 485 yen
10h ago
TAK
Alkermes selling off on limited data disclosure, says BofA
PremiumThe Fly
Alkermes selling off on limited data disclosure, says BofA
9d ago
TAK
ALKS
Takeda receives FDA clearance for HyHub, HyHub Duo
PremiumThe Fly
Takeda receives FDA clearance for HyHub, HyHub Duo
9d ago
TAK
Avidity, Phathom mentioned as potential takeout targets at Needham
PremiumThe Fly
Avidity, Phathom mentioned as potential takeout targets at Needham
13d ago
BMY
NVO
Keros Therapeutics announces first patient dosed in Phase 3 RENEW trial
PremiumThe FlyKeros Therapeutics announces first patient dosed in Phase 3 RENEW trial
13d ago
TAK
KROS
Buy Rating for Takeda Pharmaceutical Driven by Successful Phase 3 Trials of Oveporexton
Premium
Ratings
Buy Rating for Takeda Pharmaceutical Driven by Successful Phase 3 Trials of Oveporexton
15d ago
TAK
Morning Movers: Sonnet BioTherapeutics skyrockets after $888M combination
Premium
The Fly
Morning Movers: Sonnet BioTherapeutics skyrockets after $888M combination
16d ago
AZN
TAK
Takeda announces oveporexton studies met all primary, secondary endpoints
PremiumThe Fly
Takeda announces oveporexton studies met all primary, secondary endpoints
16d ago
TAK
Takeda Pharmaceutical Releases Corporate Governance Report
PremiumCompany Announcements
Takeda Pharmaceutical Releases Corporate Governance Report
21d ago
6K
TAK
Takeda Pharmaceutical Issues $2.4 Billion in Guaranteed Notes
PremiumCompany Announcements
Takeda Pharmaceutical Issues $2.4 Billion in Guaranteed Notes
28d ago
6K
TAK
Takeda Pharmaceutical’s 149th Shareholders Meeting Approves Key Resolutions
PremiumCompany Announcements
Takeda Pharmaceutical’s 149th Shareholders Meeting Approves Key Resolutions
29d ago
6K
TAK
Takeda’s 2025 Report Highlights Strong Growth and Leadership Transition
PremiumCompany AnnouncementsTakeda’s 2025 Report Highlights Strong Growth and Leadership Transition
1M ago
6K
TAK
Takeda announces FDA approval of Gammagard Liquid ERC
Premium
The Fly
Takeda announces FDA approval of Gammagard Liquid ERC
1M ago
TAK
Takeda Completes Share Repurchase Program in May 2025
Premium
Company Announcements
Takeda Completes Share Repurchase Program in May 2025
2M ago
6K
TAK
Takeda Defends Leadership Amid Shareholder Voting Recommendations
PremiumCompany Announcements
Takeda Defends Leadership Amid Shareholder Voting Recommendations
2M ago
6K
TAK
Takeda reports EC approves Adcetris combination for Hodgkin lymphoma
PremiumThe Fly
Takeda reports EC approves Adcetris combination for Hodgkin lymphoma
2M ago
TAK
Positive Outlook for Takeda Pharmaceutical Co: Buy Rating Supported by Promising Phase 3 Data and Projected Sales for Rusfertide
PremiumRatings
Positive Outlook for Takeda Pharmaceutical Co: Buy Rating Supported by Promising Phase 3 Data and Projected Sales for Rusfertide
2M ago
TAK
Protagonist, Takeda announces Phase 3 VERIFY study met primary endpoint
PremiumThe Fly
Protagonist, Takeda announces Phase 3 VERIFY study met primary endpoint
2M ago
TAK
PTGX
Veeva price target raised to $300 from $270 at Needham
PremiumThe FlyVeeva price target raised to $300 from $270 at Needham
2M ago
CRM
TAK
Takeda Reports Changes in Subsidiaries and Associates as of May 28, 2025
Premium
Company Announcements
Takeda Reports Changes in Subsidiaries and Associates as of May 28, 2025
2M ago
6K
TAK
Takeda Announces CEO Succession and Advocates for Healthcare Reforms
Premium
Company Announcements
Takeda Announces CEO Succession and Advocates for Healthcare Reforms
2M ago
6K
TAK

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >